Where the Money Goes

You are here

Home » Accelerator Programs » Reach Grants

Reach Grants

This award is designed to move hypothesis-driven research toward the clinic. A successful application will identify an unmet clinical need relevant to the care of patients with pediatric cancer and describe how the work performed will allow for the translation of hypothesis-driven research to the clinic, keeping broader clinical testing and implementation in view. A maximum of $250,000 in total costs will be awarded over two years.

Download the 2025 Reach Grant Application Guidelines

Immuno-therapeutic Targeting of CD56 in CBA2T3/GLIS2-AML in Children

Co-investigator: Dr. Colin Correnti

Principal Investigator Name: 

Soheil Meshinchi, MD/PhD

Project Title: 

Immuno-therapeutic Targeting of CD56 in CBA2T3/GLIS2-AML in Children

Year Awarded: 

2018

Cancer Research Category: 

Category of Grant: 

Medical, Nurse Researcher, Quality of LIfe: 

Institution: 

Identifying a Therapeutic Partner for TAK228 for Pediatric Phase II Brain Tumor Studies

Co-investigators: Dr. Kristine Glunde, Dr. Barbara Slusher and Dr. Charles Eberhart

Principal Investigator Name: 

Eric H. Raabe, MD/PhD

Project Title: 

Identifying a Therapeutic Partner for TAK228 for Pediatric Phase II Brain Tumor Studies

Year Awarded: 

2018

Cancer Research Category: 

Category of Grant: 

Medical, Nurse Researcher, Quality of LIfe: 

Institution: 

Epigenetic Targeted Therapy and Resistance in Pediatric Rhabdoid Tumor

Co-investigator: Dr. Ali Zhang

Principal Investigator Name: 

Rintaro Hashizume, MD/PhD

Project Title: 

Epigenetic Targeted Therapy and Resistance in Pediatric Rhabdoid Tumor

Year Awarded: 

2018

Cancer Research Category: 

Category of Grant: 

Medical, Nurse Researcher, Quality of LIfe: 

Institution: 

Therapeutic Targeting of PGBD5-induced DNA Repair Dependency in Pediatric Solid Tumors

Background

Principal Investigator Name: 

Alex Kentsis, MD/PhD

Project Title: 

Therapeutic Targeting of PGBD5-induced DNA Repair Dependency in Pediatric Solid Tumors

Year Awarded: 

2017

Cancer Research Category: 

Category of Grant: 

Institution: 

Targeting Chondroitin Sulphate Proteoglycan 4 (CSPG4) in Glioblastoma

Background

Principal Investigator Name: 

Gianpietro Dotti, MD & Barbara Savoldo, MD/PhD

Project Title: 

Targeting Chondroitin Sulphate Proteoglycan 4 (CSPG4) in Glioblastoma

Year Awarded: 

2017

Cancer Research Category: 

Category of Grant: 

Medical, Nurse Researcher, Quality of LIfe: 

Institution: 

Phase I Study of Lentivirus Engineered Autologous AML Cells Expressing IL-12 in Children and Young Adults with Relapsed AML

Background
Acute myeloid leukemia (AML) is the second-most common type of leukemia in children. AML progresses rapidly and nearly 50 percent of children who are treated for AML experience a recurrence of their disease. After this recurrence, the survival rates are dismal, measured in weeks to months rather than years. Treatment failure is the primary reason for recurrence. Discovering and testing new treatment regimens is urgently needed to improve survival for childhood AML. 

Principal Investigator Name: 

Michael Burke, MD & Jeffrey Medin, MD/PhD

Project Title: 

Phase I Study of Lentivirus Engineered Autologous AML Cells Expressing IL-12 in Children and Young Adults with Relapsed AML

Year Awarded: 

2017

Cancer Research Category: 

Category of Grant: 

Institution: 

Astatine-211 Meta-Astatobenzylguanidine ([211At]MABG) Targeted Radiotherapy for Disseminated Neuroblastoma

Background

Principal Investigator Name: 

John Maris, MD

Project Title: 

Astatine-211 Meta-Astatobenzylguanidine ([211At]MABG) Targeted Radiotherapy for Disseminated Neuroblastoma

Year Awarded: 

2016

Cancer Research Category: 

Category of Grant: 

Medical, Nurse Researcher, Quality of LIfe: 

Institution: 

University of Illinois

Background

Testicular cancer is the most common cancer among teenagers and young men between the ages of 15 and 35. Approximately 80% of patients can be cured with current therapies. However these therapies have not changed greatly since the mid-1980s and are very toxic. This results in substantial long-term side effects that greatly impact quality of life for many decades. In addition, 15-20% of patients cannot be cured even with the cytotoxic drugs and die.

 

Project Goal

Principal Investigator Name: 

Michael Spinella, Ph.D.

Project Title: 

DNA Methylation Inhibitor Therapy for Testicular Germ Cell Tumors

Year Awarded: 

2014

Cancer Research Category: 

Category of Grant: 

Medical, Nurse Researcher, Quality of LIfe: 

Institution: 

National Cancer Institute

Background

Principal Investigator Name: 

Andre Nussenzweig, Ph.D.

Project Title: 

Targeted Inhibition of the DNA Damage Response Pathway: A Novel Intervention in the Treatment of Pediatric Leukemias

Year Awarded: 

2014

Cancer Research Category: 

Category of Grant: 

Medical, Nurse Researcher, Quality of LIfe: 

Institution: 

Pages

Featured Hero

Chris Ramirez

Chris loves baseball – he has a history of playing for his high school team and is a longtime fan of the San Francisco Giants. However, when he was in high school, Chris began having strange symptoms. Today, Chris is a three-time survivor of glioblastoma.
Read more »